|
1
|
1. Siegel RL, Miller KD and Jemal A:
Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saif MW: Pancreatic neoplasm in 2012: An
update. Tissue is an issue. JOP. 13:124–127. 2012.PubMed/NCBI
|
|
3
|
Ansari D, Tingstedt B, Andersson B,
Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M
and Andersson R: Pancreatic cancer: Yesterday, today and tomorrow.
Future Oncol. 12:1929–1946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin QJ, Yang F, Jin C and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aroldi F, Bertocchi P, Rosso E, Prochilo T
and Zaniboni A: Pancreatic cancer: Promises and failures of target
therapies. Rev Recent Clin Trials. 11:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeSantis CE, Ma J, Gaudet MM, Newman LA,
Miller KD, Goding Sauer A, Jemal A and Siegel RL: Breast cancer
statistics, 2019. CA Cancer J Clin. 69:438–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu T and Dai Y: Tumor microenvironment and
therapeutic response. Cancer Lett. 387:61–68. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frankel T, Lanfranca MP and Zou W: The
role of tumor microenvironment in cancer immunotherapy. Adv Exp Med
Biol. 1036:51–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki
M, Kosuge T, Kanai Y and Hiraoka N: Immune cell infiltration as an
indicator of the immune microenvironment of pancreatic cancer. Br J
Cancer. 108:914–923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hinshaw DC and Shevde LA: The tumor
microenvironment innately modulates cancer progression. Cancer Res.
79:4557–4566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu J, Chen J, Feng Y, Tian H and Chen X:
Tumor microenvironment as the ‘regulator’ and ‘target’ for gene
therapy. J Gene Med. 21:e30882019. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ho WJ, Jaffee EM and Zheng L: The tumour
microenvironment in pancreatic cancer-clinical challenges and
opportunities. Nat Rev Clin Oncol. 17:527–540. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dougan SK: The pancreatic cancer
microenvironment. Cancer J. 23:321–325. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian
Y, Ni B, Lu B and Wang H: An increased abundance of
tumor-infiltrating regulatory T cells is correlated with the
progression and prognosis of pancreatic ductal adenocarcinoma. PLoS
One. 9:e915512014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu L, Zhao G, Wu W, Rong Y, Jin D, Wang
D, Lou W and Qin X: Low intratumoral regulatory T cells and high
peritumoral CD8(+) T cells relate to long-term survival in patients
with pancreatic ductal adenocarcinoma after pancreatectomy. Cancer
Immunol Immunother. 65:73–82. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lacalle RA, Blanco R, Carmona-Rodríguez L,
Martín-Leal A, Mira E and Mañes S: Chemokine receptor signaling and
the hallmarks of cancer. Int Rev Cell Mol Biol. 331:181–244. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bian X, Xiao YT, Wu T, Yao M, Du L, Ren S
and Wang J: Microvesicles and chemokines in tumor microenvironment:
Mediators of intercellular communications in tumor progression. Mol
Cancer. 18:502019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan KW, Evrard M, Tham M, Hong M, Huang C,
Kato M, Prevost-Blondel A, Donnadieu E, Ng LG and Abastado JP:
Tumor stroma and chemokines control T-cell migration into melanoma
following Temozolomide treatment. Oncoimmunology. 4:e9787092015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karin N and Wildbaum G: The role of
chemokines in shaping the balance between CD4(+) T Cell subsets and
its therapeutic implications in autoimmune and cancer diseases.
Front Immunol. 6:6092015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meng W, Xue S and Chen Y: The role of
CXCL12 in tumor microenvironment. Gene. 641:105–110. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Wang YF, Wu B, Zhong ZX, Wang KX,
Yang LQ, Wang YQ, Li YQ, Gao J and Li ZS: Intraepithelial attack
rather than intratumorally infiltration of CD8+T lymphocytes is a
favorable prognostic indicator in pancreatic ductal adenocarcinoma.
Curr Mol Med. 17:689–698. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haider S, Wang J, Nagano A, Desai A,
Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T, Marshall JF,
Kocher HM, et al: A multi-gene signature predicts outcome in
patients with pancreatic ductal adenocarcinoma. Genome Med.
6:1052014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang J, Dumartin L, Mafficini A, Ulug P,
Sangaralingam A, Alamiry NA, Radon TP, Salvia R, Lawlor RT, Lemoine
NR, et al: Splice variants as novel targets in pancreatic ductal
adenocarcinoma. Sci Rep. 7:29802017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang G, He P, Tan H, Budhu A, Gaedcke J,
Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, et al:
Integration of metabolomics and transcriptomics revealed a fatty
acid network exerting growth inhibitory effects in human pancreatic
cancer. Clin Cancer Res. 19:4983–4993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang G, Schetter A, He P, Funamizu N,
Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, et al:
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity
and predicts clinical outcome in pancreatic ductal adenocarcinoma.
PLoS One. 7:e315072012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang J, Wang Y, Luo Y, Fu J, Zhang Y, Li
Y, Xiao Z, Lou Y, Qiu Y and Zhu F: Computational advances of tumor
marker selection and sample classification in cancer proteomics.
Comput Struct Biotechnol J. 18:2012–2025. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
R Core Team R: A language and environment
for statistical computing. R Foundation for Statistical Computing;
Vienna, Austria: 2014, http://www.R-project.org/
|
|
29
|
Chen H and Boutros PC: VennDiagram: A
package for the generation of highly-customizable Venn and Euler
diagrams in R. BMC Bioinformatics. 12:352011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Allen PJ, Kuk D, Castillo CF, Basturk O,
Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide
V, He J, et al: Multi-institutional validation study of the
American joint commission on cancer (8th edition) changes for T and
N staging in patients with pancreatic adenocarcinoma. Ann Surg.
265:185–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Legler DF and Thelen M: Chemokines:
Chemistry, biochemistry and biological function. Chimia (Aarau).
70:856–859. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luster AD: Chemokines-chemotactic
cytokines that mediate inflammation. N Engl J Med. 338:436–445.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zlotnik A and Yoshie O: The chemokine
superfamily revisited. Immunity. 36:705–716. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu PF, Lu ZP, Cai BB, Tian L, Zou C, Jiang
KR and Miao Y: Role of CXCL12/CXCR4 signaling axis in pancreatic
cancer. Chin Med J (Engl). 126:3371–3374. 2013.PubMed/NCBI
|
|
35
|
Wald O, Shapira OM and Izhar U:
CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic
roles and therapeutic potential. Theranostics. 3:26–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goto M and Liu M: Chemokines and their
receptors as biomarkers in esophageal cancer. Esophagus.
17:113–121. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee HJ and Jo DY: The role of the
CXCR4/CXCL12 axis and its clinical implications in gastric cancer.
Histol Histopathol. 27:1155–1161. 2012.PubMed/NCBI
|
|
38
|
Sleightholm RL, Neilsen BK, Li J, Steele
MM, Singh RK, Hollingsworth MA and Oupicky D: Emerging roles of the
CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.
Pharmacol Ther. 179:158–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Salomonnson E, Stacer AC, Ehrlich A, Luker
KE and Luker GD: Imaging CXCL12-CXCR4 signaling in ovarian cancer
therapy. PLoS One. 8:e515002013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Samarendra H, Jones K, Petrinic T, Silva
MA, Reddy S, Soonawalla Z and Gordon-Weeks A: A meta-analysis of
CXCL12 expression for cancer prognosis. Br J Cancer. 117:124–135.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Feig C, Jones JO, Kraman M, Wells RJ,
Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL,
et al: Targeting CXCL12 from FAP-expressing carcinoma-associated
fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic
cancer. Proc Natl Acad Sci USA. 110:20212–20217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Beider K, Begin M, Abraham M, Wald H,
Weiss ID, Wald O, Pikarsky E, Zeira E, Eizenberg O, Galun E, et al:
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple
myeloma tumor growth. Exp Hematol. 39:282–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wong D, Kandagatla P, Korz W and Chinni
SR: Targeting CXCR4 with CTCE-9908 inhibits prostate tumor
metastasis. BMC Urol. 14:122014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Okabe H, Beppu T, Ueda M, Hayashi H,
Ishiko T, Masuda T, Otao R, Horlad H, Mima K, Miyake K, et al:
Identification of CXCL5/ENA-78 as a factor involved in the
interaction between cholangiocarcinoma cells and cancer-associated
fibroblasts. Int J Cancer. 131:2234–2241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Walz A, Burgener R, Car B, Baggiolini M,
Kunkel SL and Strieter RM: Structure and neutrophil-activating
properties of a novel inflammatory peptide (ENA-78) with homology
to interleukin 8. J Exp Med. 174:1355–1362. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Keane MP, Belperio JA, Xue YY, Burdick MD
and Strieter RM: Depletion of CXCR2 inhibits tumor growth and
angiogenesis in a murine model of lung cancer. J Immunol.
172:2853–2860. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Katoh H, Wang D, Daikoku T, Sun H, Dey SK
and Dubois RN: CXCR2-expressing myeloid-derived suppressor cells
are essential to promote colitis-associated tumorigenesis. Cancer
Cell. 24:631–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kawamura M, Toiyama Y, Tanaka K, Saigusa
S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M:
CXCL5, a promoter of cell proliferation, migration and invasion, is
a novel serum prognostic marker in patients with colorectal cancer.
Eur J Cancer. 48:2244–2251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Roca H, Jones JD, Purica MC, Weidner S,
Koh AJ, Kuo R, Wilkinson JE, Wang Y, Daignault-Newton S, Pienta KJ,
et al: Apoptosis-induced CXCL5 accelerates inflammation and growth
of prostate tumor metastases in bone. J Clin Invest. 128:248–266.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gao Y, Guan Z, Chen J, Xie H, Yang Z, Fan
J, Wang X and Li L: CXCL5/CXCR2 axis promotes bladder cancer cell
migration and invasion by activating PI3K/AKT-induced upregulation
of MMP2/MMP9. Int J Oncol. 47:690–700. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cui D, Zhao Y and Xu J: Activation of
CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S
phase transition of papillary thyroid carcinoma cells and activates
JNK and p38 pathways. Cancer Biol Ther. 20:608–616. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Soler-Cardona A, Forsthuber A, Lipp K,
Ebersberger S, Heinz M, Schossleitner K, Buchberger E, Gröger M,
Petzelbauer P, Hoeller C, et al: CXCL5 facilitates melanoma
cell-neutrophil interaction and lymph node metastasis. J Invest
Dermatol. 138:1627–1635. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Forsthuber A, Lipp K, Andersen L,
Ebersberger S, Graña-Castro O, Ellmeier W, Petzelbauer P,
Lichtenberger BM and Loewe R: CXCL5 as regulator of neutrophil
function in cutaneous melanoma. J Invest Dermatol. 139:186–194.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH,
Feng H, Zheng MH, Zhao JK and Lu AG: CXCL5 induces tumor
angiogenesis via enhancing the expression of FOXD1 mediated by the
AKT/NF-κB pathway in colorectal cancer. Cell Death Dis. 10:1782019.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yildirim K, Colak E, Aktimur R, Gun S,
Taskin MH, Nigdelioglu A, Aktimur SH, Karagöz F and Ozlem N:
Clinical value of CXCL5 for determining of colorectal cancer. Asian
Pac J Cancer Prev. 19:2481–2484. 2018.PubMed/NCBI
|
|
57
|
Wang L, Shi L, Gu J, Zhan C, Xi J, Ding J
and Ge D: CXCL5 regulation of proliferation and migration in human
non-small cell lung cancer cells. J Physiol Biochem. 74:313–324.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu K, Yu S, Liu Q, Bai X, Zheng X and Wu
K: The clinical significance of CXCL5 in non-small cell lung
cancer. Onco Targets Ther. 10:5561–5573. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hu B, Fan H, Lv X, Chen S and Shao Z:
Prognostic significance of CXCL5 expression in cancer patients: A
meta-analysis. Cancer Cell Int. 18:682018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Speetjens FM, Kuppen PJ, Sandel MH, Menon
AG, Burg D, van de Velde CJ, Tollenaar RA, de Bont HJ and
Nagelkerke JF: Disrupted expression of CXCL5 in colorectal cancer
is associated with rapid tumor formation in rats and poor prognosis
in patients. Clin Cancer Res. 14:2276–2284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Gu Y, Feng Q, Liu H, Zhou Q, Hu A,
Yamaguchi T, Xia S and Kobayashi H: Bioinformatic evidences and
analysis of putative biomarkers in pancreatic ductal
adenocarcinoma. Heliyon. 5:e023782019. View Article : Google Scholar : PubMed/NCBI
|
